Biohaven closes $200M public offering at $7.50 per share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $26 at Morgan Stanley
November 17, 2025 7:38 AM ESTMorgan Stanley analyst Terence Flynn lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $26.00 (from $54.00) while maintaining a Overweight rating.
The analyst comments "BHVN announced on 10/4 that it received a Complete Response Letter (CRL) from the FDA regarding its NDA for... More



